Career Summary: Dr. Amado is Vice President of Oncology at GlaxoSmithKline (Philadelphia, PA), a position he has held since 2008, where he heads the Solid Oncology Medicine Development department. From 2003–2008 he was Executive Director of Amgen. He received his M.D. from UCLA. His specialty is hematology/oncology. He took over the research work undertaken by Dr. Pauline Chen sponsored by her 2001 STOP CANCER Award, which was subsequently carried on by Dr. Richard Finn when Dr. Amado joined Amgen.
Year STOP CANCER Award was received: 2001 RCDA
Description of research performed: Dr. Amado's career has focused on development of drugs to treat various types of solid-tumor cancers, including liver cancer.
Results of research: Dr. Amado has played a central role in the development of drugs that are currently being used in clinical trials and treatments.